679

680

681

682

683

684

685

686

687

688 689 690

691

692


693

694

677 12. Using 100x magnification, view the counting grid.

13. The counting grid on the hemocytometer consists of nine sections, four of which are counted (upper left, upper right, lower left, and lower right, see **Figure 9-1**). Each section counted consists of four by four grids. Starting at the top left and moving clockwise, count all cells in each of the four by four grids. Some cells will be touching the outside borders of the square, but only count those that touch the top and right borders of the square. This value is then used in the calculation below to get to the desired concentration of 200,000 cells/mL.

Figure 9-1 Hemocytometer Counting Grid.



The volume of each square is 10⁻⁴ mL, therefore:

Cells/mL = (average number per grid) $\times 10^{-4}$ mL. $\times 1/(\text{starting dilution})$.

Starting dilution: 20mL (for T150 flasks)

Harvested cells for a T150 flask are suspended in 20 mL of estrogen-free DMEM and sampled for determination of concentration of cells/mL.

Example Calculation:

- Grids 1, 2, 3, and 4 are counted and provide the following data:
- 695 o 50, 51, 49, and 50: average number of cells per grid is equal to 50.

- 696 Cells/mL = 50 cells per grid \div 10⁻⁴ mL volume of grid = 50 X 10⁻⁴ cells/mL (or 500,000
- 697 cells/mL)

706

709

- 698 Total # of Cells Harvested = 500,000 cells/mL x 20 mL
- 699 Desired Concentration (or Concentration Final) = 200,000 cells/mL
- 700 Formula: (Concentration Final x Volume Final = Concentration Initial x Volume Initial)
- 702 Concentration Final = 200,000 cells/mL
- 703 Concentration Initial = 500,000 cells/mL
- 704 Volume Initial = 20 mL
- 705 Volume Final to be solved for.
- Therefore: 200,000 cells/mL x Volume $_{Final} = 500,000$ cells/mL x 20 mL
- 708 Solving for Volume Final we find = 50 mL
- 710 Therefore, add 30 mL of DMEM Growth media to the cell suspension for a total volume of 50
- 711 mL, which will yield the desired concentration of 200,000 cells/mL for plating.
- 712 14. This dilution scheme will give a concentration of 200,000 cells/mL. 200 μ L of
- this cell suspension is used for each well of a 96-well plate (i.e., 40,000 cells per
- 714 well).
- 715 15. Remove a 96-well plate from its sterile packaging. Use a repeater pipetter to
- pipette 200 μL of cell suspension into each well except the outside ring of wells.
- 16. Use a repeater pipetter to pipette 200 µL of estrogen-free DMEM to the outer
- 718 wells of the 96-well plate.
- 719 17. Incubate plate(s) in an incubator (see conditions in **Section 9.0**) for a minimum of
- 720 24 hours, but no longer than 48 hours before dosing.

min, as before.

test substance is solubilized in DMSO.

744

745

746

721 Two T150 flasks containing cells at 80% to 90% confluence will typically yield sufficient cells 722 to fill four 96-well plates (not including the perimeter wells). PREPARATION OF TEST SUBSTANCES 723 10.0 The solvent used for dissolution of test substances is 100% DMSO. All test substances should be 724 725 allowed to equilibrate to room temperature before being dissolved and diluted. Test substance 726 solutions (except for reference standards and controls) should not be prepared in bulk for use in subsequent tests. Test substances are to be used within 24 hours of preparation. Solutions should 727 728 not have noticeable precipitate or cloudiness. 729 All information on weighing, solubility testing, and calculation of final concentrations for test 730 substances, reference standards and controls is to be recorded in the study notebook. 731 10.1 **Determination of Test Substance Solubility** Prepare a 200 mg/mL solution of the test substance in 100% DMSO in a 15 mL 732 733 conical tube. 734 Vortex to mix 735 If the substance does not go into solution after vigorous vortexing, sonicate for 10 736 min. If the 200 mg/mL solution has visible precipitate or is cloudy, add an additional 9 737 738 mL of DMSO to the conical tube (20 mg/mL), then vortex and/or sonicate for 10 min. as before. 739 740 If the 20 mg/mL solution has visible precipitate or is cloudy, prepare a 2 mg/mL 741 solution in a 15 mL conical tube. Vortex and/or sonicate for 10 min. as before. If the 2 mg/mL solution has visible precipitate or is cloudy, add an additional 9 742 mL of DMSO to the conical tube (200 µg/mL), then vortex and/or sonicate for 10 743

7. Continue testing, using 1/10 less substance in each subsequent attempt until the

747 748		ess in 100% DMSO, the solubility of the test substance must be determined in the 1%
749		99% estrogen-free DMEM mixture used for LUMI-CELL® ER testing.
750		8. Add 2 μL of the highest concentration of the test substance/DMSO solution to a
751		13 mm test tube.
752		9. Add 400 μ L estrogen-free DMEM to the test tube and vortex gently,
753		10. If cloudiness or precipitate develop, vortex for up to 10 minutes.
754 755		11. If vortexing does not dissolve test substance, sonicate test substance for up to 10 minutes.
756 757		12. If test substance has visible precipitate or is cloudy return to Section 10.1 step 7 to try the next lower concentration for the test substance.
758	The Tes	sting Facility shall forward the results from the solubility tests assay to the SMT through
759	the desi	gnated contacts in electronic format and hard copy upon completion of testing.
760	11.0	PREPARATION OF REFERENCE STANDARD, CONTROL AND TEST
761		SUBSTANCE STOCK SOLUTIONS FOR RANGE FINDER AND
762		COMPREHENSIVE TESTING
763	All info	rmation on preparation of test substances, reference standards and controls is to be
764	recorde	d in the study notebook.
765	11.1	Preparation of Ral/E2 Stock Solutions
766	E2 and	raloxifene stocks are prepared separately and then combined into Ral/E2 stocks, which
767	are then	used to prepare dosing solutions in Section 12.
768	41.1.1	E2 Stock Solution
769	The fina	al concentration of the E2 stock solution is $5.0 \times 10^{-3} \mu\text{g/mL}$. Prepare the E2 stock as
770	shown i	n Table 11-1.
771		

771 Table 11-1 Preparation of E2 Stock Solution

Step#	Action	DMSO	E2 Concentration
1	Make a 10 mg/mL stock solution in 100% DMSO in a 4mL vial.	-	10 mg/mL
2	Transfer 10 µL E2 solution from Step #1 to a new 4 mL vial.	Add 990 μL of 100% DMSO. Vortex to mix.	100 μg/mL
3	Transfer 10 µL E2 solution from Step #2 to a new 4mL vial.	Add 990 μL of 100% DMSO. Vortex to mix.	1 μg/mL
4	Transfer 100 μL E2 solution from Step #3 to a new glass container large enough to hold 15 mL.	Add 9.90 mL of 100% DMSO. Vortex to mix.	1.0 x 10 ⁻² μg/mL
5	Transfer 5 mL E2 solution from Step #4 to a new glass container large enough to hold 15 mL	Add 5 mL of 100% DMSO. Vortex to mix.	5.0 x 10 ⁻³ μg/mL

773 11.1.2 Raloxifene Working Stock Solution

772

776

781

Prepare a 2.5 μg/mL raloxifene working stock solution as shown in **Table 11-2**.

775 Table 11-2 Preparation of Raloxifene Working Stock Solution

Step#	Action	DMSO	Raloxifene Concentration
1	Make a 10 mg/mL solution of raloxifene in a 4 mL glass vial.	-	1.0 x 10 ⁴ μg/mL
2	Transfer 10 µL raloxifene solution from Step #1 to a new 4 mL vial.	Add 990 μL of 100% DMSO. Vortex to mix.	100 μg/mL
3	Transfer 150 μL raloxifene solution from Step #2 to a new 4 mL vial.	Add 2.850 mL of 100% DMSO. Vortex to mix.	5 μg/mL
4	Transfer 1.5 mL raloxifene solution from Step #3 to a new 13 mm test tube.	Add 1.5 mL of 100% DMSO. Vortex to mix.	2.5 μg/mL

777 11.2 Ral/E2 Range Finder Stock

778 11.2.1 Raloxifene Dilutions

- Number three 4 mL vials with the numbers 1 to 3 and use the raloxifene solution prepared in
- 780 **Section 11.1.2** to make raloxifene dilutions as shown **Table 11-3**.

781 Table 11-3 Preparation of Raloxifene Reference Standard for Range Finder Testing

Step#	Action	DMSO	Raloxifene Concentration
1	Transfer 500 µL of the raloxifene working stock solution to a new 4 mL vial.		2.5 μg/mL
2	Transfer 50 μL of the raloxifene working stock solution to a new 4 mL vial.	Add 500 µL of 100% DMSO. Vortex to mix.	2.50 x 10 ⁻¹ μg/mL
3	Transfer 2 µL of the raloxifene working stock solution to a new 4 mL vial.	Add 500 µL of 100% DMSO. Vortex to mix.	1.00 x 10 ⁻² μg/mL

782

783 11.2.2 Ral/E2 Dilutions for Range Finder Stock:

Add 500 μ L of the 5 x 10⁻³ μ g/mL E2 solution prepared in **Section 11.1.1** to each of the

785 raloxifene dilution vials prepared in Section 11.2.1. Vortex each tube to mix. The final

786 concentrations for raloxifene and E2 are listed in **Table 11-4**.

787 Table 11-4 Concentrations of Raloxifene and E2 in the

Ral/E2 Range Finder Stock Solution

Tube #	Raloxifene (µg/ml)	E2 (µg/ml)
1	1.25	2.5 x 10 ⁻³
2	1.25 x 10 ⁻¹	2.5×10^{-3}
3	5.00 x 10 ⁻³	2.5 x 10 ⁻³

789

790

788

11.3 Ral/E2 Comprehensive Testing Stock

791 11.3.1 Raloxifene Dilutions for Comprehensive Testing Stock

792 Use the raloxifene solution prepared in Section 11.1.2 to make a 9 point serial dilution of

793 raloxifene as shown **Table 11-5**.

794 Table 11-5 Preparation of Raloxifene 9-Point Serial Dilution

Step#	Action	DMSO	Discard	Raloxifene Concentration
1	Transfer 500 μL of the raloxifene working stock solution to a new 4 mL vial.	-	-	2.5 μg/mL
2	Transfer 500 μL of the raloxifene working stock solution to a new 4 mL vial.	Add 500 µL of 100% DMSO. Vortex to mix.	-	1.25 μg/mL

Step#	Action	DMSO	Discard	Raloxifene Concentration
. 3	Transfer 500 μL raloxifene solution from Step #2 to a new 4 mL vial.	Add 500 µL of 100% DMSO. Vortex to mix.	-	6.25 x 10 ⁻¹ μg/mL
4	Transfer 500 μL raloxifene solution from Step #3 to a new 4 mL vial.	Add 500 µL of 100% DMSO. Vortex to mix.	-	3.13 x 10 ⁻¹ μg/mL
5	Transfer 500 μL raloxifene solution from Step #4 to a new 4 mL vial.	Add 500 µL of 100% DMSO. Vortex to mix.	-	1.56 x 10 ⁻¹ μg/mL
6	Transfer 500 μL raloxifene solution from Step #5 to a new 4 mL vial.	Add 500 µL of 100% DMSO. Vortex to mix.	-	7.81 x 10 ⁻² μg/mL
7	Transfer 500 µL raloxifene solution from Step #6 to a new 4 mL vial.	Add 500 µL of 100% DMSO. Vortex to mix.	-	3.91 x 10 ⁻² μg/mL
8	Transfer 500 μL raloxifene solution from Step #7 to a new 4 mL vial.	Add 500 µL of 100% DMSO. Vortex to mix.		1.95 x 10 ⁻² μg/mL
9	Transfer 500 μL raloxifene solution from Step #8 to a new 4 mL vial.	Add 500 µL of 100% DMSO. Vortex to mix.	Discard 500 µL from Tube #9	9.77 x 10 ⁻³ μg/mL

11.3.2 Ral/E2 Dilutions for Comprehensive Testing Stock:

Add 500 µL of the 5 x 10⁻³ µg/mL E2 solution prepared in **Section 11.1.1** to each of the 9 raloxifene dilution vials (including the working stock solution in Tube #1). Vortex each tube to mix. The final concentrations for raloxifene and E2 are listed in **Table 11-6**.

Table 11-6 Concentrations of Raloxifene and E2 in the Ral/E2 Stock Solution

Tube#	Raloxifene (µg/mL)	E2 (μg/mL)
1	1.25	2.5×10^{-3}
2	6.25×10^{-1}	2.5×10^{-3}
3	3.13×10^{1}	2.5 x 10 ⁻³
4	1.56 x 10 ⁻¹	2.5 x 10 ⁻³
5	7.81×10^2	2.5×10^{-3}
6	3.91 x 10 ⁻²	2.5×10^{-3}
7	1.95 x 10 ⁻²	2.5×10^{-3}
8	9.77 x 10 ⁻³	2.5 x 10 ⁻³
9	4.88 x 10 ⁻³	2.5×10^{-3}

795

796

800

802	11.4	Flavone/E2 Stock Solution
803	To prepa	are the flavone/E2 stock solution, proceed as follows:
804		1. Prepare 1 mL of 10 mg/mL flavone
805		2. Add 1 mL of the $5x10^{-3}$ µg/mL E2 (prepared as in Section 11.1.1) to the 10
806		mg/mL flavone. This will make a working solution of 5 mg/mL flavone with
807	•	$2.5 \times 10^{-3} \mu \text{g/mL E}$ 2.
808	12.0	PREPARATION OF REFERENCE STANDARD, CONTROL AND TEST
809		SUBSTANCE DOSING SOLUTIONS FOR RANGE FINDER AND
810		COMPREHENSIVE TESTING
811	12.1	Preparation of Reference Standard and Control Dosing Solutions for Range
812		Finder Testing
813	Range fi	nder testing is conducted on 96-well plates using three concentrations of Ral/E2 in
814	duplicate	e as the reference standard. Three replicate wells for the DMSO, and E2 controls are
815	included	on each plate.
816	All "dos	ing solutions" of test substance concentrations are to be expressed as $\mu g/mL$ in the study
817	notebool	k and in all laboratory reports.
818	Dosing s	solutions are to be used within 24 hours of preparation.
819	12.1.1	Preparation of Ral/E2 Reference Standard Range Finder Dosing Solutions
820		1. Label two sets of 13 mm glass tubes with the numbers 1 to 3.
821		2. Add 4 μL of Ral/E2 stock from tube #1 from Section 11.2.2 to the two 13 mm
822		glass test tubes labeled #1.
823		3. Add 4 μL of Ral/E2 stock from tube #2 from Section 11.2.2 to the two 13 mm
324		glass test tubes labeled #2. Repeat for tubes #3.
325		4. Add $400 \mu L$ of estrogen-free DMEM to each tube and vortex to mix.
326	12.1.2	Preparation of DMSO Control Range Finder Dosing Solution
327		1. Add 4 μL of 100% DMSO to three 13 mm glass test tubes.

828 2. Add 400 μL of estrogen-free DMEM to each tube and vortex to mix.

12.1.3 Preparation of E2 Control Range Finder Dosing Solution

- 1. Add 2 μ L of the E2 stock from **Section 11.1.1** to three 13 mm glass test tube.
- 2. Add 400 μL of estrogen-free DMEM to each tube and vortex to mix.

12.2 Preparation of Test Substance Dosing Solutions for Range Finder Testing

Range finder experiments are used to determine the concentrations of test substance to be used during comprehensive testing. Antagonist range finding for coded substances consists of six point, logarithmic serial dilutions.

To prepare test substance dosing solutions:

829

830

831

832

836

837

838

839

840

841

843

844

845846

847

1. Label two sets of six glass 13 mm test tubes with the numbers 1 through 6 and place them in a test tube rack. Perform a serial dilution of test substance as shown in **Table 12-1**.

Table 12-1 Preparation of Test Substance Serial Dilution for Range Finder Testing

Tube #	100% DMSO	Test Substance ¹	Final Volume
1	10 μL of test substance solution from Section 10.1		100 μL
2	90 µL	10 μL of test substance solution from Section 10.1	100 μL
3	90 μL	10 μL from Tube #2	100 μL
4	90 μL	10 μL from Tube #3	100 μL
5	90 μL	10 μL from Tube #4	100 μL
6	90 μL	10 μL from Tube #5	100 μL

Vortex tubes #2 through 5 before removing test substance/DMSO solution to place in the next tube in the series.

²Vortex all tubes to mix media, test substance, and E2.

2. Transfer test substance/DMSO solutions to new tubes and add E2 as shown in **Table 12-2**.

²Transfer test substance/DMSO solutions to a new set of 13 mm test tubes.

849

850

851

847 Table 12-2 Addition of E2 to Test Substance Serial Dilution for Range Finder Testing

Tube Number	Test Substance	E2	Remove	Estrogen- free DMEM ³	Final Volume
1	Transfer 4 µL of test substance from Tube #1 in Section 12.2 step 1 to a new tube	Add 4 µL of the 5 x 10 ⁻³ µg/mL E2 solution prepared in Section 11.1.1 . Vortex to mix.	Remove and discard 4 μL from Tube #1	400 μL	404 μL
2	Transfer 4 µL of test substance from Tube #2 to a new tube	Add 4 µL of the 5 x 10 ⁻³ µg/mL E2 solution prepared in Section 11.1.1 Vortex to mix.	Remove and discard 4 µL from Tube #2	400 μL	404 μL
3	Transfer 4 µL of test substance from Tube #3 to a new tube	Add 4 µL of the 5 x 10 ⁻³ µg/mL E2 solution prepared in Section 11.1.1 . Vortex to mix.	Remove and discard 4 µL from Tube #3	400 μL	404 μL
4	Transfer 4 µL of test substance from Tube #4 to a new tube	Add 4 µL of the 5 x 10 ⁻³ µg/mL E2 solution prepared in Section 11.1.1 . Vortex to mix.	Remove 4 μL from Tube #4	400 μL	404 μL
· 5	Transfer 4 µL of test substance from Tube #5 to a new tube	Add 4 µL of the 5 x 10 ⁻³ µg/mL E2 solution prepared in Section 11.1.1 . Vortex to mix.	Remove 4 µL from Tube #5	400 μL	404 μL
6	Transfer 4 μL of test substance from Tube #6 to a new tube	Add 4 µL of the 5 x 10 ⁻³ µg/mL E2 solution prepared in Section 11.1.1 . Vortex to mix.	Remove 4 µL from Tube #6	400 µL	404 μL

Determination of whether a substance is positive in range finder testing and selection of starting concentrations for comprehensive testing will be discussed in **Section 14.0**.

12.3 Preparation of Reference Standard and Control Dosing Solutions for

Comprehensive Testing

Comprehensive testing is conducted on 96-well plates using nine concentrations of Ral/E2 in duplicate as the reference standard. Three replicate wells for the DMSO, E2 and flavone/E2

sometrols are included on each plate.

All "dosing solutions" of test substance concentrations are to be expressed as $\mu g/mL$ in the study notebook and in all laboratory reports.

Store dosing solutions at room temperature. Use within 24 hours of preparation.

12.3.1 <u>Preparation of Ral/E2 Reference Standard Dosing Solutions for Comprehensive</u>

860 Testing

851

852

853

854

856

857

859

861

862

863

864

865

866

868

In preparation for making Ral/E2 double serial dilutions, label two sets of nine glass 13 mm test tubes with the numbers 1 through 9 and place them in a test tube rack. Tube number 1 will contain the highest concentration of raloxifene (**Table 12-3**).

Table 12-3 Preparation of Ral/E2 Reference Standard Dosing Solution for Comprehensive Testing

Tube Number	Ral/E2 Stock	Estrogen- free DMEM	Final Volume
1	4 μL of Tube #1 from Section 11.3.2	400 μL	404 μL
2	4 μL of Tube #2 from Section 11.3.2	400 μL	404 µL
3	4 μL of Tube #3 from Section 11.3.2	400 μL	404 μL
4	4 μL of Tube #4 from Section 11.3.2	400 μL	404 μL
5	4 μL of Tube #5 from Section 11.3.2	400 μL	404 μL
6	4 μL of Tube #6 from Section 11.3.2	400 μL	404 μL
7	4 μL of Tube #7 from Section 11.3.2	400 µL	404 μL
8	4 μL of Tube #8 from Section 11.3.2	400 μL	404 μL
9	4 μL of Tube #9 from Section 11.3.2	400 μL	404 μL

867 12.3.2 <u>Preparation of DMSO Control Comprehensive Testing Dosing Solution</u>

1. Add 4 μ L of 100% DMSO to three 13 mm glass test tubes.

869		2.	Add 400 µL of estrogen-free DMEM to each tube and vortex to mix.
870	12.3.3	Pre	eparation of E2 Control Comprehensive Testing Dosing Solution
871		1.	Add 2 μL of the E2 stock from Section 11.1.1 to three 13 mm glass test tube.
872		2.	Add 400 μL of estrogen-free DMEM to each tube and vortex to mix.
873	12.3.4	Pre	eparation of Flavone/E2 Control Comprehensive Dosing Solution
874		1.	Add 4 μL of flavone/E2 from Section 11.4 to three 13 mm glass test tubes.
875		2.	Add 400 μL of estrogen-free DMEM to each tube and vortex to mix.
876	12.4	Pro	eparation of Test Substance Dosing Solutions for Comprehensive Testing
877	Compre	hensi	ve testing experiments are used to determine whether a substance possesses ER
878	antagoni	ist act	tivity in the LUMI-CELL® ER test method. Antagonist comprehensive testing for
879	coded su	ıbstar	nces consists of 11 point, double serial dilutions, with each concentration tested in
880	triplicate	e well	s of the 96-well plate.
881	To prepa	are te	st substance dosing solutions for comprehensive testing:
882		1.	Determine the concentration at which maximal antagonism occurs in the range
883			finder experiment. Start an 11-point serial dilution curve at a 20-fold higher
884			concentration than the concentration causing a maximal antagonist response (i.e.,
885			if the maximum antagonist response occurred at 0.01 mg/mL, start the serial
886			dilution curve at 0.2 mg/mL).
887		2.	If there is no observable antagonist response in the range finder experiment, start
888			the serial dilution at the maximum soluble concentration.
889		3.	Label three sets of 11 glass 13 mm test tubes with the numbers 1 through 11 and
890			place them in a test tube rack. Prepare three serial dilutions as indicated in Table
891			12-4.
892			

Table 12-4 Preparation of Test Substance Dosing Solutions for Comprehensive Testing

Tube Number	100% DMSO	Test Substance ¹	Discard	E2 Testing Stock	Discard	Estrogen- free DMEM ²	Final Volume
1	-	4 µL of test substance solution from Section 10.2.4 step 1	-	4 μL	4 μL	400 μL	404 μL
2	4 μL	4 μL of test substance solution from Section 10.2.4 step 1	. -	4 μL	4 μL	400 μL	404 μL
3	4 μL	4 μL from Tube #2	-	4 μL	4 μL	400 μL	404 μL
4	΄ 4 μL	4 μL from Tube #3	-	4 μL	4 μL	400 μL	404 μL
5	4 μL	4 μL from Tube #4	-	4 μL	4 μL	400 μL	404 μL
6	4 μL	4 μL from Tube #5	-	4 μL	4 μL	400 μL	404 μL
7	4 μL	4 μL from Tube #6	_	4 μL	4 μL	400 μL	404 μL
8	4 μL	4 μL from Tube #7	- ,	4 μL	4 μL	. 400 μL	404 μL
9	4 μL	4 μL from Tube #8	-	4 μL	4 μL	400 μL	404 μL
10	4 μL	4 μL from Tube #9	-	4 μL	4 μL	400 μL	404 μL
11	4 μL	4 μL from Tube #10	4 μL	4 μL	4 μL	400 μL	404 μL

Vortex tubes #2 through 10 before removing test substance/DMSO solution to place in the next tube in the series.

13.0 GENERAL PROCEDURES FOR THE TESTING OF CODED SUBSTANCES

Range finder experiments are used to determine the concentrations of test substance to be used during comprehensive testing. Comprehensive testing experiments are used to determine whether a substance possesses ER antagonist activity in the LUMI-CELL® ER test method.

General procedures for range finder and comprehensive testing are nearly identical. For specific details (such as plate layout) of range finder testing see **Section 14.0**. For specific details of comprehensive testing, see **Section 15.0**.

²Vortex all tubes to mix media, test substance, and E2.

904	13.1	Application of Reference Standard, Control and Test Substances
905		1. Remove the 96-well plates (from Section 9.2.3 step 18) from the incubator;
906		inspect them using an inverted microscope. Only use plates in which the cells in
907		all wells receive a score of 1 according to Table 11-1 .
908		2. Remove medium by inverting the plate onto blotter paper. Gently tap plate against
909		the bench surface to remove residual liquid trapped in the wells.
910		3. Add 200 μ L of medium, reference standard, control or test substance to each well
911		(see Sections 14.0 and 15.0 for specific plate layouts).
912		4. Return plates to incubator (see Section 9.0 for details) for 19 to 24 hours to allow
913		maximal induction of luciferase activity in the cells.
914	13.1.1	Preparation of Excel® Data Analysis Template
915		1. In Excel®, open a new "AntICCVAMTemplate" and save it with the appropriate
916		project name as indicated in the NICEATM Style Guide.
917		2. Add appropriate information regarding the assay to the "Compound Tracking"
918		tab.
919		3. Enter substance testing information to the "List" page (i.e. Project /Sample ID,
920		Concentration, and Comments (or compound name). This should populate the
921		"Template", "Compound Mixing" and "Visual Inspection" tabs with the
922		appropriate information for the experiment.
923		4. Save the newly named project file
924		5. Print out either the "List" or "Template" page for help with dosing the 96-well
925		plate. Sign and date the print out and store in study notebook.
926	13.2	Visual Evaluation of Cell Viability
927		1. 19 to 24 hours after dosing the plate, remove the plate from the incubator and
928		remove the media from the wells by inverting the plate onto blotter paper. Gently
929		tap plate against the bench surface to remove residual liquid trapped in the wells.

- Use a repeat pipetter to add 50 μL 1X PBS to all wells. Immediately remove PBS
 by inversion.
 - 3. Using an inverted microscope, inspect all of the wells used in the 96-well plate and record the visual observations using the scores in **Table 13-1**.

Table 13-1 Visual Observation Scoring

Viability Score	Brief Description ¹
1	Normal Cell Morphology and Cell Density
2	Altered Cell Morphology and/or Small Gaps between Cells
3	Altered Cell Morphology and/or Large Gaps between Cells
4	Few (or no) Visible Cells
1P	Score of 1 with Precipitate
2P	Score of 2 with Precipitate
3P	Score of 3 with Precipitate
4P	Score of 4 with Precipitate
5P	Unable to View Cells Due to Precipitate

¹Reference micrographs will be provided by NICEATM.

936

937

940

941

942

943

944

949

935

932

933

934

13.3 Lysis of Cells for LUMI-CELL® ER

- 938 1. Apply the reflective white backing tape to the bottom of the 96-well plate (this will increase the effectiveness of the luminometer).
 - 2. Add 30μL 1X lysis reagent to the assay wells and place the 96-well plate on an orbital shaker for one minute.
 - Remove plate from shaker and measure luminescence (as described in Section 11.5).

13.4 CellTiter-Glo® Assessment of Cell Viability

- When considered necessary, a quantitative evaluation of cell viability will be performed with the Promega CellTiter-Glo® assay system. CellTiter-Glo® uses luminescence as an indicator of the number of cells per plate and therefore must be conducted in parallel with the LUMI-CELL® ER test method (i.e., both test methods cannot be conducted on the same plate).
 - 1. Dose and incubate cells under the same conditions as for LUMI-CELL® ER.


950 Remove plates from incubator and discard the medium by inverting the plate onto 951 blotter paper. Gently tap plate against the bench surface to remove residual liquid 952 trapped in the wells. 953 3. Use a repeat pipetter to add 50 µL 1X PBS to all assay wells. Immediately 954 remove PBS by inversion. 955 Examine all wells used under an inverted microscope. Make notes of any well with codes described in Table 13-1. 956 957 Place white backing tape on the bottom of the 96-well plate. 958 6. Add 100 µL estrogen-free DMEM to each well containing cells. Add 100 µL CellTiter-Glo® reagent to each well containing cells. 959 960 Place plate on an orbital shaker for 1 minute to induce cell lysis. 8. 961 9 Incubate (see Section 9.0 for details) for 10 min. 962 10. Measure luminescence promptly. Do not add luciferase reagent to CellTiter-Glo® 963 plates. 964 13.5 **Measurement of Luminescence** 965 Luminescence is measured in the range of 300 to 650 nm, using an injecting luminometer and 966 with software that controls the injection volume and measurement interval. Light emission from each well is expressed as relative light units (RLU) per well. The luminometer output is saved as 967 raw data in an Excel® spread sheet. A hard copy of the luminometer raw data should be signed. 968 969 dated and stored in the study notebook. 970 13.6 **Data Analysis** LUMI-CELL® ER uses an Excel® spreadsheet to collect and adjust the RLU values obtained 971 from the luminometer and a GraphPad Prism® template to analyze and graph data. Plate 972 reduction is calculated using unadjusted RLU values. 973 The Excel® spreadsheet subtracts background luminescence (average DMSO solvent control 974 RLU value) from test substance, reference standard and control RLU values. Test substance, 975 976 reference standard, and control RLU values are then adjusted relative to the highest Ral/E2

977	reference sta	ndard RLU value, which is set to 10,000. After adjustment, values are transferred to
978	GraphPad Pi	rism [®] for data analysis and graphing.
979	13.6.1 <u>Co</u>	orrection and Adjustment of Luminometer Data
980	The following	ng steps describe the procedures required to populate the Excel® spreadsheet that has
981	been configu	red to collect and adjust the RLU values obtained from the luminometer.
982	1.	Open the raw data file and the corresponding experimental Excel® spreadsheet
983		from Section 13.1.1.
984	2.	Copy the raw data using the Excel® copy function, then paste the copied data into
985		cell C22 of the "RAW DATA" tab in the experimental Excel® spreadsheet using
986		the Paste Special - Values command. This position corresponds to position B2 in
987		the table labeled Table 1 in this tab.
988	3.	Examine the DMSO data in Table 1 of the Excel® spreadsheet to determine
989	•	whether there are any potential outliers. See Section 13.6.2 for further explanation
990		of outlier determinations.
991	4.	If an outlier is identified, perform the following steps to remove the outlier from
992		calculations:
993		 correct the equation used to calculate DMSO background in Table 1,
994		e.g., if outlier is located in cell G24, adjust the calculation in cell H42 to
995		read =AVERAGE(F24.H24,I24)
996		• then correct the equation used to calculate the average DMSO value in
997		Table 2, e.g., following the above example, adjust cell M44 to read
998		=AVERAGE(F36,H36,I36)
999		then correct the equation used to calculate the standard deviation of the
1000		DMSO value in Table 2, e.g., following the above example, adjust cell
1001		M45 to read =STDEV(F36,H36,I36)
1002	5.	Excel® will automatically subtract the background (the average DMSO control
1003		value) from all of the RLU values in Table 1 and populate Table 2 with these
1004		adjusted values.

1005	6.	To calculate plate reduction, identify the cell containing the Ral/E2 replicate that
1006		has the lowest RLU value and the cell containing the RLU value for the same
1007		concentration in the corresponding Ral/E2 replicate (e.g., if the lowest RLU value
1008		for Ral/E2 is located in cell E23, the corresponding cell would be E22).
1009	7.	Identify the cell containing the Ral/E2 replicate that has the highest RLU value
1010		and the cell containing the RLU value for the same concentration in the
1011		corresponding Ral/E2 replicate
1012	8.	Click into cell D16 and enter the cell numbers from Section 13.6.1 step 6 into the
1013	·	numerator and the cell numbers from step 7 into the denominator.
1014	9.	Click on the "ER Antagonist Report" tab.
1015	10.	The data for the Ral/E2 reference standard, DMSO, E2, and Flavone/E2 replicates
1016		populate the left portion (columns A-F) of the spreadsheet. The data is
1017		automatically placed into an Excel® graph.
1018	11.	To set the highest RLU value for the reference standard to 10,000 RLU, go to cell
1019		D2 of "ER Antagonist Report" tab and check the formula contained within that
1020		cell. The divisor should be the cell number of the cell containing the highest
1021		averaged Ral/E2 RLU value (column E).
1022	12.	Copy the data into GraphPad Prism® for graphing and analysis as indicated in the
1023		NICEATM Prism® users guide.
1024	13.6.2 <u>De</u> t	termination of Outliers
1025	The Study Di	rector will use good statistical judgment for determining "unusable" wells that will
1026	be excluded fi	rom the data analysis and will provide an explanation in the study notebook for any
1027	excluded data	. This judgment for data acceptance will include Q-test analysis.
1028	The formula f	For the Q test is:
	Outlier – Nea	rest Neighbor
1029	Range (Highe	est – Lowest)
1030	where the out	lier is the value proposed for exclusion, the nearest neighbor is the value closest to
1031	the outlier an	d the range is the range of the three values

1032	If the value of this ratio is greater than 0.94 (the Q value for the 90% confidence interval for a
1033	sample size of three), the outlier may be excluded from data analysis. For Ral/E2 reference
1034	standard replicates (sample size of two), any adjusted RLU value for a replicate at a given
1035	concentration of Ral/E2 is considered and outlier if its value is more than 20% above or below
1036	the adjusted RLU value for that concentration in the historical database.
1037	13.6.3 <u>Acceptance Criteria</u>
1038	Acceptance or rejection of a test is based on evaluation of reference standard and control results
1039	from each experiment conducted on a 96-well plate. Results are compared to quality controls
1040	(QC) for these parameters derived from the historical database, which are summarized below.
1041	 Reduction: Plate reduction, as measured by dividing the averaged highest Ral/E2
1042	reference standard RLU value by the averaged lowest Ral/E2 reference standard
1043	RLU value, must be greater than three fold.
1044	• Reference standard results: Calculated Ral/E2 reference standard IC50 values must
1045	be within 2.5 times the standard deviation of the historical database IC_{50} mean
1046	value.
1047	Solvent control results: DMSO control RLU values must be within 2.5 times the
1048	standard deviation of the historical solvent control mean RLU value.
1049	• E2 control results: E2 control RLU values must be within 2.5 times the standard
1050	deviation of the historical E2 control mean RLU value.
1051	• Positive control results: Flavone/E2 control RLU values must be within 2.5 times
1052	the standard deviation of the historical database flavone/E2 control mean RLU
1053	value.
1054	An experiment that fails any single acceptance criterion will be discarded and repeated.
1055	13.6.4 <u>Calculation of Relative IC₅₀ Values</u>
1056	Relative IC ₅₀ values are calculated as directed in the NICEATM Prism® users guide. The
1057	concentration curve must have a sigmoidal shape and reach saturation at the highest and lowest
1058	concentrations tested (Figure 13-1) for Prism® to calculate a valid relative IC ₅₀ value.

Figure 13-1 Example Concentration Curve for Calculation of Relative IC₅₀ Value



1060

1061

1062

1063

1064

10651066

1059

The mathematical model used by Prism® to calculate an IC₅₀ value uses the Hill function as described in **Section 6.0**.

13.6.5 <u>Calculation of Absolute IC₅₀ Values</u>

Calculate an absolute IC₅₀ (Eli Lilly 2005) for all substances that are positive for antagonism at one or more concentrations that cause a 50% reduction in response compared to the E2 control (**Figure 13-2**).